HeartFlow Dividends and Buybacks
Dividend criteria checks 0/6
HeartFlow does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-7.7%
Buyback Yield
| Total Shareholder Yield | -7.7% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
HTFL: Clinical Evidence And AI Adoption Will Test Execution And Margin Durability
HeartFlow's updated analyst price target ticks higher to about $44.78, with analysts pointing to broad price target increases following Q2 beats, stronger guidance, and growing confidence in the company’s AI driven cardiac diagnostics platform. Analyst Commentary Recent research updates on HeartFlow show a mix of enthusiasm and caution, with most analysts focusing on how Q2 execution, updated guidance, and the AI driven product suite feed into long term growth expectations and valuation frameworks.HeartFlow: An Impressive MedTech Growth Play
Summary HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution. Despite ongoing operating losses, a robust net cash position and significant addressable market suggest further upside, but current valuation tempers immediate enthusiasm. Read the full article on Seeking AlphaHTFL: Beat And Raise Trajectory Will Test Execution And Competitive Risks
HeartFlow's analyst fair value estimate has shifted from $37.00 to about $42.13 as analysts factor in stronger Q2 results, higher guidance and updated long term assumptions on growth, margins and valuation multiples. Analyst Commentary Recent Street research on HeartFlow clusters around a similar message.HTFL: Beat And Raise Performance Will Face Sector Pressure Ahead
HeartFlow's analyst price target has moved to $37.00, with analysts citing the recent Q1 sales beat, raised full year sales guidance, and sector multiple shifts as key drivers of the updated fair value inputs. Analyst Commentary Analysts covering HeartFlow are updating their views around the new US$37.00 price target, focusing on how recent results and sector moves affect valuation, execution risk, and future growth potential.Companies Like HeartFlow (NASDAQ:HTFL) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if HTFL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HTFL's dividend payments have been increasing.
Dividend Yield vs Market
| HeartFlow Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (HTFL) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Healthcare Services) | 1.2% |
| Analyst forecast (HTFL) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate HTFL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HTFL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate HTFL's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HTFL has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 03:36 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HeartFlow, Inc. is covered by 10 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| William Plovanic | Canaccord Genuity |
| Eugene Mannheimer | Freedom Capital Markets |